| Business Strategy |
|
The objective of Therosteon is to develop and commercialize a balanced portfolio of products in the field of bone diseases based on innovative R&D. Through collaborations with top-tier academic groups and with biotechs or pharma companies Therosteon aims at creating maximal value at minimal costs. Therosteon intends to raise soft-money to support these collaborations and keep the burn rate low. Short term value will be increased through deals with biotechs or pharma companies that want a technology license in order to use our OsteoBLAST platform (partner-led programs). Long term value will be created to in-house drug development and in-licensing of compounds that are further along in the drug- development pipeline. |
Newsflash
Nov 5. Dec 15. |
